Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSix weeks into Wegovy, most people are still in the dose-escalation phase — which means the medicine hasn't yet reached its full working strength. Clinical trial data shows meaningful weight loss builds over months, not weeks, with the largest reductions recorded well past the six-week mark. That said, some early changes are real, measurable, and worth understanding before you assume the treatment isn't working. Wegovy is a prescription-only medicine; a clinician assesses whether it's right for you before any prescription is issued.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The headline figure from the STEP 1 trial (published in the New England Journal of Medicine) is around 15% average weight reduction over 68 weeks at the 2.4mg maintenance dose. What that figure doesn't show is the trajectory: weight loss in the trial was gradual and cumulative, with participants still losing meaningful amounts well into months five and six. The first six weeks covered, at most, the 0.25mg starting dose and the step to 0.5mg. These are tolerability doses. Their job is to let your body adjust to the medicine, not to produce the results the 2.4mg maintenance dose delivers.
Across the early weeks of the trial, reported weight changes were modest compared with what came later. That pattern is consistent: you are not seeing Wegovy working at full strength at week six. Expecting 68-week results in less than two months misreads how the medicine is designed to work.
Our detailed breakdown of Wegovy weight loss by week tracks this trajectory more granularly if you want the specific dose-by-dose picture.
A question our prescribers hear regularly: "I'm six weeks in and I've only lost a couple of kilograms) is it working?" The short answer is almost certainly yes, but the medicine is still ramping up.
By week six you are typically moving from 0.5mg toward 1.0mg. Each dose increase takes around four weeks to settle before the next step. Appetite suppression deepens at each level, and gastric emptying slows progressively. Some people notice a meaningful shift in hunger from the very first pen; others feel very little until they reach 1.7mg or higher. Both experiences sit within the range described in the trial data reviewed by the NICE appraisal of semaglutide (TA875).
There is also a body-composition factor. On a calorie deficit, the body loses water alongside fat in the early weeks, sometimes a lot of it. The scales may move less than you expect once that initial drop settles. That does not mean fat loss has stopped. It means the medicine is doing what it should while your body recalibrates.
If week 5 felt similarly flat, the detail on why the fifth week can stall covers that specific window more fully.
If the scales haven't moved at all by week six, a few things are worth checking before drawing conclusions. First: has anything offset the calorie deficit? Alcohol, large social meals, a period of reduced activity due to illness or injury, all are common in a six-week window and can mask real appetite reduction. Second: are you measuring weight at the same time of day, on the same day each week? Daily fluctuations of one to two kilograms from fluid shifts are normal and can make a genuine downward trend invisible if you're checking at inconsistent times.
Third, and worth taking seriously: some people do find the lower doses produce very little appetite change. If you are genuinely eating the same amount you were before treatment with no suppression at all at week six, that is a clinical question, not something to troubleshoot alone. Your prescriber can look at the full picture, including whether your titration schedule is progressing appropriately.
Longer-term patterns, including what the 12-week point typically looks like, are covered in our Wegovy 12-week weight loss guide.
Clinical trials record averages across hundreds of participants. Your result at week six is shaped by variables those averages smooth over: your starting BMI, how much of your excess weight is visceral versus subcutaneous fat, your sleep quality, stress levels, and how closely you've been able to reduce calorie intake. The NHS patient information for semaglutide emphasises that Wegovy works alongside a reduced-calorie diet and increased physical activity, the medicine lowers appetite, but the food environment around that still matters.
Protein intake is worth particular attention. On a significant calorie deficit in the early months of treatment, muscle preservation becomes important; many people find higher protein intake helps them feel full on less food and supports strength-training if they're doing it. Personal dietary advice is something a prescriber or dietitian can tailor; the principle is well-established.
One thing that is fully in your control from day one: consistency. If you want to understand more about how semaglutide works as the active ingredient in Wegovy, that can help set realistic expectations for each stage of titration. Skipped or delayed doses slow the titration process and, with it, the results.
For a fuller look at how average weekly loss tends to vary across the whole treatment course, Wegovy weight loss per week covers the data in more detail. And if you're still deciding whether Wegovy or another licensed treatment is the right fit, our weight loss treatment overview sets out the options.
If you'd like a prescriber to review your situation and assess whether you're a suitable candidate, you can start your free consultation with the nume clinical team.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.